A pancreatic cancer drug discovered in professors Paul Bingham and Zuzana Zachar’s lab in the Department of Biochemistry and Cell Biology at Stony Brook University has now entered Phase III, or multi-center testing stage.
About one in four deaths each year in the United States are caused by heart disease, according to the Centers for Disease Control and Prevention. Coronary heart disease in particular is the number one killer of women, yet approximately two-thirds of women who die unexpectedly of the disease show no prior knowledge of having the disease or even symptoms.
Just a couple of days ago it was revealed that three of Stony Brook’s professors, Dr. Russell A. Mittermeier, Dr. Carl Safina, and Dr. Patricia C. Wright, made up three out of the six finalists in the running for the Indianapolis Prize, which is generally recognized as “the world’s leading award for animal conservation,” according to Morgan Lyle’s article in Newsday.com.
A research scientist in Stony Brook’s Department of Molecular Genetics & Microbiology by the name of Dr. Nobuhide Ueki is pioneering a technique to directly address the limitations of cancer treatment. He was further motivated to pursue this field of study after losing both of his grandparents to cancer. His lab is focused on creating a drug delivery system that will selectively target cancer cells, leaving normal cells healthy.